The Ross Revolution: Long-Term Data Revive a Living Valve Solution for Young Aortic Patients (2025 Update). Ross procedure outperforms bioprosthetic aortic valve replacement among younger patients
The Ross Revolution: Long-Term Data Revive a Living Valve Solution for Young Aortic Patients (2025 Update). Ross procedure outperforms bioprosthetic aortic valve replacement among younger patients
Source: European Journal of Cardio-Thoracic Surgery, October 9 2025
Keynotes:
1. The Ross procedure replaces the diseased aortic valve with the patient’s own pulmonary valve, offering a living and durable alternative to artificial valves.
2. It is mainly used for aortic stenosis or regurgitation in younger patients (<60 years) seeking long-term outcomes without lifelong anticoagulation.
3. 2025 Mount Sinai data (455 patients, 15 years): 12-year reintervention rate 4%, survival equal to the general population.
4. Provides excellent durability, natural valve motion, and low risk of stroke or infection when performed in expert centers.
5. Compared to TAVR, Ross is preferred for younger, low-risk patients, while TAVR suits older or high-risk individuals.
6. Overall, the Ross procedure remains the gold standard for young adults needing aortic valve replacement, combining natural physiology with long-term survival.
